Expanding clinical pipeline, rising research investment and increasing diversification into influenza, RSV, oncology and next-generation RNA technologies
mRNA Vaccines Market
Dublin, Aug. 26, 2026 (GLOBE NEWSWIRE) — The “mRNA Vaccines Market by Target Indication (RSV Infection, Metastatic / R / R Head and Neck Cancer, Influenza, Norovirus Acute Gastroenteritis, and Mononucleosis) and Geographical Regions (North America, Europe, and Asia-Pacific) – Trends and Forecast Till 2035” has been added to ResearchAndMarkets.com’s offering.
The global mRNA vaccines market for non-COVID applications is projected to grow from approximately USD 9 million in 2026 to USD 7.04 billion by 2035, representing a compound annual growth rate of 109% during the forecast period. Market expansion is being supported by advancing clinical pipelines, continued investment in manufacturing and delivery technologies, and the growing application of mRNA platforms across infectious diseases and oncology.
mRNA Vaccines Market Growth and Trends
The mRNA vaccines market is moving beyond its pandemic-driven origins toward a more diversified commercial landscape. Respiratory syncytial virus, influenza, cytomegalovirus, norovirus and other infectious diseases have become important areas of development. Oncology is also emerging as a major opportunity, with more than 100 mRNA-based candidates under investigation for cancer-related indications.
Personalized cancer vaccines represent a particularly promising segment of the clinical pipeline. Developers are evaluating patient-specific mRNA therapies designed around individual tumor neoantigens, with several candidates progressing through mid-stage clinical development. BioNTech, for example, has published clinical data from cancer vaccine programs currently undergoing Phase II evaluation, supporting expectations for potential commercialization toward the end of the decade.
Clinical and regulatory progress continues to strengthen confidence in the technology. Seven mRNA vaccines have secured regulatory approval and become commercially available across the broader market, while a substantially larger group of candidates is progressing through mid- and late-stage trials. Moderna, BioNTech and Sanofi rank among the most active industry sponsors, and close to 70% of ongoing mRNA vaccine clinical trials are managed or funded by commercial organizations.
Key Market Growth Drivers
The speed and adaptability of mRNA vaccine development remain central market drivers. Manufacturers can update vaccine sequences rapidly in response to antigenic drift, emerging pathogens and changing public health requirements. Advances in lipid nanoparticle delivery, cell-free manufacturing and production scalability are also improving stability, efficiency and commercial viability.
Next-generation technologies, including self-amplifying RNA, circular RNA and trans-amplifying RNA platforms, could further enhance dose efficiency, immune-response durability and the range of addressable indications. These innovations are expected to create additional opportunities in infectious disease prevention, oncology, rare diseases and personalized medicine.
Intellectual property and partnership activity also reflect growing industry confidence. More than 1,060 patents related to mRNA vaccine technologies have been filed or granted worldwide. Strategic collaborations involving pharmaceutical companies, specialist biotechnology developers and governments are accelerating technology transfer, domestic manufacturing and pipeline development. Pfizer and Sanofi are among the leading large pharmaceutical companies pursuing partnerships with specialized mRNA developers.
Market Challenges
Despite its strong outlook, the mRNA vaccines market faces commercial, operational and regulatory barriers. Demand has normalized from pandemic-era levels, requiring developers to establish sustainable markets for non-COVID indications. Reimbursement pathways, physician adoption and public confidence remain less established in several emerging application areas.
Cold-chain requirements may continue to restrict access in cost-sensitive and infrastructure-constrained markets. Manufacturing expertise and capacity are also concentrated among a limited number of established companies, potentially creating supply bottlenecks as more products approach commercialization. In addition, evolving regulatory frameworks for novel mRNA indications may extend development timelines in certain jurisdictions.
Competitive intensity is expected to rise in high-value indications such as influenza and RSV. Successful developers will increasingly need to demonstrate differentiated efficacy, convenient dosing, favorable safety profiles or compelling combination-vaccine strategies.
Key mRNA Vaccines Market Insights
- Influenza is projected to account for the largest share of the mRNA vaccines market by 2035.
- More than 100 mRNA-based candidates are under investigation for oncology-related indications.
- Close to 70% of ongoing clinical trials are managed or funded by industry participants.
- More than 1,060 mRNA vaccine technology patents have been filed or granted worldwide.
- Moderna, BioNTech and Sanofi are among the most active sponsors of mRNA vaccine clinical research.
- Continued investment in combination vaccines and next-generation RNA platforms is expected to support long-term market expansion.
Influenza Expected to Become the Leading Target Indication
Influenza is forecast to capture the largest market share by 2035. The recurring annual demand for seasonal influenza vaccines aligns with scalable mRNA manufacturing infrastructure. Rapid sequence updates may also enable manufacturers to improve strain matching by finalizing vaccine composition closer to the beginning of each flu season.
Commercial opportunities are further supported by the potential development of combination respiratory vaccines. In April 2026, the European Commission authorized Moderna’s mRNA-1083 combination influenza and COVID-19 vaccine, representing a significant milestone for dual respiratory mRNA products. Moderna’s seasonal influenza candidate, mFlusiva, is also under FDA review following clinical data in adults aged 50 to 64.
Regional Market Outlook
North America is expected to remain the largest and fastest-growing regional mRNA vaccines market through 2035. The region benefits from established mRNA design expertise, lipid nanoparticle capabilities, advanced manufacturing infrastructure, significant public-sector support and a strong intellectual property base. Efficient regulatory pathways and concentrated investment from leading biotechnology companies further reinforce its market position.
Europe is projected to remain a major contributor to global revenue, supported by an expanding biotechnology ecosystem, coordinated public health procurement and continued regulatory progress. Asia-Pacific is also expected to record meaningful growth as China, South Korea and other markets invest in domestic manufacturing, pandemic-preparedness infrastructure and local mRNA technology platforms.
The market analysis covers North America, Europe, Asia-Pacific, the Middle East and North Africa, and Latin America, with country-level assessments of the US, Canada, Germany, the UK, France, Italy, Spain, China, Japan, South Korea, Australia, Saudi Arabia, the UAE, Brazil and Argentina.
Leading Companies in the mRNA Vaccines Market
- Arcturus Therapeutics
- BioNTech
- CureVac
- Ethris
- Gennova Biopharmaceuticals
- Immorna
- Innovac Therapeutics
- Kernal Biologics
- Moderna
- Providence Therapeutics
- Recode Therapeutics
- Strand Therapeutics
- Suzhou Abogen Biosciences
- Turn Biotechnologies
- Walvax
Report Coverage
The report provides market sizing and opportunity analysis by target indication and geography. It also evaluates the mRNA vaccine development landscape by clinical phase, target indication, administration route, RNA platform and developer profile. Additional coverage includes company profiles, clinical trial analysis, patent activity, partnerships, funding, investments, competitive forces, market drivers, restraints and emerging opportunities.
The study incorporates insights from business development leaders, executives, researchers, drug-delivery specialists and medical professionals across the US, Europe, Asia-Pacific and Australia. It is designed to help pharmaceutical companies, biotechnology developers, investors and other stakeholders evaluate market potential, identify competitive advantages and support data-driven strategic planning.
Research Benefits
- Detailed revenue forecasts for the overall market and major subsegments
- Analysis of commercial opportunities, competitive barriers and industry risks
- Clinical trial, patent, partnership and investment intelligence
- Profiles of established companies and emerging mRNA vaccine developers
- Excel data packs covering the report’s analytical modules
- Up to 15% complimentary report customization
- Research team walkthrough and qualifying report updates
With an expanding clinical pipeline, rising research investment and increasing diversification into influenza, RSV, oncology and next-generation RNA technologies, the global non-COVID mRNA vaccines market is positioned for exceptional growth through 2035.
Key Attributes
| Report Attribute | Details |
| No. of Pages | 269 |
| Forecast Period | 2026-2035 |
| Estimated Market Value (USD) in 2026 | $9 Million |
| Forecasted Market Value (USD) by 2035 | $7040 Million |
| Compound Annual Growth Rate | 109.0% |
| Regions Covered | Global |
For more information about this report visit https://www.researchandmarkets.com/r/sutv39
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Attachment
- mRNA Vaccines Market
CONTACT:
CONTACT: ResearchAndMarkets.com
Laura Wood,Senior Press Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
